Redefining Neuroprotection: Revive’s Approach to Treating Brain Injury from Nerve Agents

posted Dec 03, 2024 9:00am  by  Revive Therapeutics Ltd
Evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. ...read more